Not a revenue story yet, but it's easy to see the appeal based on $200 per unit price point.
1M units = $200m in revenue / 5m units = $1bn revenue...globally we should be expecting multiples of the latter in terms of sales!
Once sales start in the Australian market, it will move investors a step closer to modelling commercialisation. Also, the fact the product is commercially available in Aus should lend weight to the FDA application one would think. Lower dose and fewer side effects should makes this an easy one for the FDA to approve.
News: LTP LTR Pharma Raises A$10.5 Million Through Share Placement, page-10
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
32.5¢ |
Change
-0.005(1.52%) |
Mkt cap ! $36.38M | |||
| Open | High | Low | Value | Volume |
| 33.0¢ | 34.0¢ | 32.3¢ | $69.12K | 210.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 22020 | 32.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 33.5¢ | 90303 | 2 |
View Market Depth
| Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
| LTP (ASX) Chart |